AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$ENSC

Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights

Ensysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights ~ Completed Acquisition of Cy Biopharma, Adding Lead Pipeline Asset CY200 for Complex Regional Pain Syndrome ~ ~ Submitted Phase 2a Protocol for CY200 to the UK’s Medicines and H

Original reporting
SEC EDGAR 8-K
Published Nov 12, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ENSC
Neutral
high confidence
Mentioned
$ENSC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ENSCNeutralMed
01

Why it matters

The acquisition of Cy Biopharma and progress on two pipeline candidates provide new catalysts, while the cash raise improves liquidity.

02

Market read

First‑time disclosure of financials, acquisition and pipeline milestones offers fresh data for traders; likely influences ENSC price and sector peers.

03

What to watch

Regulatory timeline for the UK MHRA review of CY200 may delay commercialization, affecting near‑term valuation.

Relevance 7/10Novelty 7/10Timing: today

Background

Ensysce Biosciences, a Nasdaq‑listed clinical‑stage biotech, disclosed its Q3 2026 financials and operational updates via an SEC 8‑K filing.

Company-level read

Ticker impact

$ENSCNeutralHigh confidence
Context

Ensysce Biosciences filed an 8‑K reporting Q3 2026 results, a recent acquisition of Cy Biopharma, cash balance of $29.7 M and progress on CY200 and PF614 pipelines.

Expected impact

potential modest upside as cash and pipeline progress offset dilution from recent financing

Evidence & confidence

First disclosure of financials and acquisition provides new material information; market may price in improved balance sheet and pipeline milestones.

Market effects

Sector

Adds momentum to the neuro‑plastogenic biotech niche and may lift peer sentiment in the pain‑therapy sector.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minor, confined to specialty biotech investors.

Counterpoint

What could challenge this read

Dilution from the $19.6 M Series C placement could pressure the stock despite cash infusion.

Key entities

  • company
    Ensysce Biosciences, Inc.

    NASDAQ: ENSC, clinical‑stage biotech focusing on CRPS and novel opioid therapies.

  • company
    Cy Biopharma, Inc.

    Acquired asset provider of CY200, a psilocybin‑based candidate for CRPS.

Read at source← All news

Related articles

$ENSCMed

Ensysce Biosciences Goes From $0.7 Million Of Quarter-End Cash To About $31 Million After Cy Biopharma Deal And Financing

Ensysce Biosciences ended Q2 2026 with $676,704 in cash but secured $31M post-quarter from acquiring Cy Biopharma and related financings. The deal adds CY200, a neuroplastogenic candidate for CRPS, as the lead asset. Proceeds will fund CY200's Phase 2 trial and existing opioid programs. Ensysce's cash runway extends into late 2027, with a potential $38.6M tranche for 2028 if milestones are met. Q2 R&D expenses rose to $2.47M, widening the net loss to $2.57M.

pulse2.com
$ENSCMed

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent

Ensysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights ~ Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome ~ ~ Up to $77 million in new funding with the acquisition of Cy Biopharma ~ ~ Com

SEC EDGAR 8-K